Cantargia

Årsstämma 23/5 2022

Cantargia

2021 - characterized by progress in a quickly changing environment

- *Strong interim clinical results in PDAC and NSCLC*
- *Strong news flow, new studies starting*
- *Competitor results*
- *Changing market conditions*

Milestones and summary

Cantargia history (as of AGM 2022)



Händelser under året 2021

2021-08-19	(R) Cantargia rapporterar uppdaterade lovande överlevnadsdata från CANFOUR-studien med nadunolimab och cellgifter i bukspottkörtelcancer	2021-09-22	(R) Cantargia: FDA tilldelar särläkemedelsstatus (Orphan Drug Designation) till nadunolimab för behandling av bukspottkörtelcancer
2021-07-01	Cantargia meddelar publicering av två vetenskapliga artiklar kring nadunolimab	2021-09-16	(R) Cantargia presenterar positiva interimsdata för kombinationsterapi med nadunolimab på ESMO-konferensen
2021-06-29	(R) Cantargia rapporterar positiva resultat för antikroppen CAN10 i en preklinisk modell av systemisk skleros	2021-09.12	(R) Cantargia: Nya positiva interimsdata för kombinationsterapi med nadunolimab i NSCLC har publicerats i ett vetenskapligt abstrakt inför årets ESMO-konferens
2021-06-08	(R) Cantargia rapporterar om opposition mot nyligen godkänt europeiskt patent	2021-09-10	(R) Cantargia erhåller regulatoriskt godkännande att påbörja den kliniska studien CESTAFOUR med nadunolimab i kombination med cellgifter
2021-05-19	(R) Cantargia rapporterar framsteg i produktionsutvecklingen och uppdaterar kring förberedelserna av klinisk studie för CAN10	2021-09.10	(R) Cantargia fullbordar patientrekryteringen till fas IIa extensionskohorten i pankreascancer inom CANFOUR-studien
2021-05-10	(R) Cantargia rapporterar behandling av första patienten i kliniska studien CESTAFOUR	2021-09-06	(R) Cantargia expanderar utvecklingen av nadunolimab i icke-skivepitel-NSCLC
2021-08-19	(R) Cantargia erhåller positivt utlåtande från EMA om särläkemedelsstatus för nadunolimab vid behandling av bukspottkörtelcancer	2021-09.01	(R) Cantargia förstärker bolagets ledningsgrupp
2021-07-01	(R) Cantargias omfattande patentskydd för målstyrda cancerterapier mot IL1RAP kvarstår efter avslutad oppositionsprocess	2021-08-30	(R) Cantargia rapporterar prekliniska data som påvisar fördelarna med nadunolimabs verkningsmekanism
2021-06-29	(R) Cantargia erhåller regulatoriskt godkännande för start av TRIFOUR-studien i trippelnegativ bröstcancer	2021-08-26	(R) Cantargia rapporterar behandling av första patienten i CAPAFOUR-studien som utvärderar kombination av nadunolimab och FOLFIRINOX i bukspottkörtelcancer
2021-08-19	(R) Cantargia expanderar CIRIFOUR-studien efter avslutad rekrytering till kombinationsarmen med pembrolizumab	2021-05-06	Cantargia tar nästa steg i utvecklingen av antikroppen CAN04 med en ny klinisk studie i trippelnegativ bröstcancer
2021-07-01	(R) Cantargia tar nästa steg i utvecklingen av nadunolimab inom trippelnegativ bröstcancer genom inlämning av klinisk ansökan för TRIFOUR-studie	2021-04-26	Cantargia presenterar nya prekliniska resultat kring antikroppen CAN10 på IMMMUNOLOGY2021
2021-06-29	(R) Cantargia breddar utvecklingen av nadunolimab i tre cancerformer och ansöker om start av fas I/II kliniska studien CESTAFOUR	2021-03-19	(R) Cantargia rapporterar positiva prekliniska resultat kring säkerhet och effekt i CAN10-projektet
2021-06-08	(R) Cantargia erhåller regulatoriskt godkännande att påbörja klinisk studie för utvärdering av nadunolimab och FOLFIRINOX i bukspottkörtelcancer	2021-03-10	(R) Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer
2021-05-19	Cantargia rapporterar positiva resultat från en pågående fas IIa klinisk studie i bukspottkörtelcancer med nadunolimab och cellgifter	2021-02-10	Cantargia meddelar att första patienten med behandlats i fas IIa extensionsdel av CANFOUR-studien i bukspottkörtelcancer
2021-05-10	Cantargia presenterar nya prekliniska data som visar att antikroppen CAN10 åstadkommer en unik förbättring av hjärtfunktion vid hjärtmuskelinflammation		

Händelser under året 2022

2022-04-27	(R) Cantargia presenterar nya kliniska data för IL1RAP-antikroppen nadunolimab vid tre sessioner på ASCO 2022	2022-02-03	(R) Cantargia rapporterar positiva säkerhetsdata från kliniska studien CIRIFOUR med nadunolimab i kombination med pembrolizumab
2022-03-10	(R) Cantargia förstärker ledningsgruppen inför kliniska studier i sen utvecklingsfas	2022-01-19	(R) Cantargia rapporterar överklagande av tredje part mot EPO:s beslut till förmån för Cantargias patent
2022-03-01	(R) Cantargia rapporterar positiva prekliniska effektdata för CAN10 som visar anti-fibrotisk och anti-inflammatorisk effekt i systemisk skleros	2022-01-14	(R) Cantargia rapporterar behandling av första patienten med trippelnegativ bröstcancer i TRIFOUR-studien
2022-02-22	(R) Cantargia rapporterar nya lovande toxikologiresultat för CAN10 och planlägger fas I-studien till 2023	2022-01-03	(R) Cantargia tar nästa steg med nadunolimab mot bukspottkörtelcancer i PanCAN:s kliniska fas 2/3-studie Precision Promise℠
2022-02-04	(R) Cantargia rapporterar behandling av första patienten med icke-skivepitel icke-småcellig lungcancer i ny arm i CANFOUR-studien		

Lead antibody nadunolimab (CAN04)

IL1RAP is overexpressed in most solid tumors

IL1RAP EXPRESSION IN SOLID TUMOR TYPES



IL1RAP-EXPRESSING CELLS IN TUMOR MICROENVIRONMENT



IL1RAP: DISTINCT OVEREXPRESSION IN TUMORS AND LOW NORMAL TISSUE REACTIVITY

NSCLC – non-small cell lung cancer
HNSCC – head and neck squamous carcinoma

cantargia

Cantargia - strategy to improve current cancer therapies



IL1RAP: A NOVEL TARGET WITH SEVERAL OPPORTUNITIES

cantargia

Cantargia – Save lives and create value through IL1RAP

Project	Disease	Type of treatment	Discovery phase	Preclinical phase	Clinical phase I	Clinical phase II	Clinical phase III	Commercial phase
CAN04 Nadunolimab	PDAC	1st line	Gemcitabine/nab-paclitaxel					
			FOLFIRINOX					
	NSCLC	1st line	Cisplatin/gemcitabine					
		2nd/3rd line	Docetaxel					
	Non-squamous NSCLC	1st/2nd line	Carboplatin/pemetrexed					
		1st line	Pembro/carboplatin/pemetrexed					
	TNBC	1st/2nd line	Carboplatin/gemcitabine					
	Biliary tract cancer	1st line	Cisplatin/gemcitabine					
	Colon cancer	3rd line	FOLFOX					
	Solid tumors	ICI combo	Pembro					
CAN10	Myocarditis; Systemic sclerosis							
CANxx	New opportunities within IL1RAP platform							

PDAC – pancreatic cancer; NSCLC – non-small cell lung cancer; TNBC – triple negative breast cancer; ICI – immune checkpoint inhibitor; Pembro – pembrolizumab

- Potentially more effective treatment against novel target in clinically validated pathway
- First in class platform technology against novel target
- Well-financed to build a broad, diversified pipeline
- Right team and clear plan to position our projects and maximize value

cantargia

Cantargia addresses NSCLC & PDAC





Non-Small Cell Lung Cancer

2.1m	**Annual global incidences**
12%	**Fraction of cancer incidence**
1.8m	**Annual global mortalities**
18%	**Fraction of cancer mortality**
19%	**Five-year survival rate**

Treatment: *Surgery, Radiation, Chemotherapy, Immunotherapy*



Pancreatic cancer

0.5m	**Annual global incidences**
3%	**Fraction of cancer incidence**
0.4m	**Annual global mortalities**
5%	**Fraction of cancer mortality**
9%	**Five-year survival rate**

Treatment: *Chemotherapy, Surgery, Radiation*

Source: WHO, The Global Cancer Observatory 2018

cantargia

Positive interim data in pancreatic cancer

Nadunolimab combination with Gem/Abraxane in 1st line (Dec 2021), n=33:

- 27% response rate with durable responses, two patients still on treatment
- Pseudoprogression-like response in 5 (15%) patients predict long PFS
- Promising PFS (7.2 mo) and OS (12.7 mo, 64 % events)

UPDATE: Results on 73 pts to be presented at ASCO 2022







PFS AND OS LONGER THAN EXPECTED GIVEN HISTORICAL CONTROL

cantargia

Combination strategy in NSCLC – Promising efficacy

	Total NSCLC (27 pts)	Historical control[1,2]	Non-squamous NSCLC (15 pts)	Historical control[3]	Squamous NSCLC (11 pts)	Historical control[4]
ORR	48%	22-28%	53%	19%	36%	38%
PFS	7.2 mo	5.1 mo	NR	-	NR	-
Ongoing treatment	11 pts (41%)	-	6 pts (40%)	-	5 pts (45%)	-



Nadunolimab combination with Gem/Cis in 1st line:

- 13 of 27 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (ORR 48% vs historical control data of 22-28%)
- No major side effects observed except those from chemotherapy or nadunolimab alone. *Neutropenia frequency higher than expected from chemo (but can be treated with dose reductions or G-CSF)*
- Trial expanding - 40 additional patients with non-squamous NSCLC

STRONG INTERIM RESULTS, UPDATE AT ASCO 2022

[1] Schiller et al, N Engl J Med 2002
[2] Scagliotti et al, J Clin Oncol 2008
[3] Gandhi et al, N Engl J Med 2018
[4] Paz-Ares et al, N Engl J Med 2018

cantargia

Safety profile is manageable and supports MOA

Grade 3 or higher AEs	Gem/Abraxane (von Hoff 2013) N=421	CANFOUR Nadunolimab/ Gem/Abraxane N=36	FOLFIRINOX (Conroy 2011) N=171
Neutropenia	38%	67%	46%
Febrile neutropenia	3%	17%	5%
Thrombocytopenia	13%	19%	9%
Anemia	13%	14%	8%
Fatigue	17%	6%	24%
Peripheral neuropathy	17%	0%	9%
Diarrhea	6%	3%	13%
Elevated ALT	ND	3%	7%
IRR	ND	3%	ND

- G-CSF is an approved therapy to counteract neutropenia; G-CSF was not used prophylactically in this trial
- The beneficial effect in fatigue and chemotherapy-induced neuropathy (nab-paclitaxel or oxaliplatin) can be explained by IL-1 blockade

UPDATE: PANCAN IS MOVING NADUNOLIMAB INTO PHASE 2/3 PDAC TRIAL

Note: Median duration of treatment 4.8 months (ref 3.9 months); most common reasons for termination: gastrointestinal events or general health deterioration. No patients discontinued due to neutropenia.

cantargia

Strong signal in non-squamous NSCLC



Nadunolimab combination with Gem/Cis in 1st line:

- Non-squamous NSCLC comprises approx. 75% of NSCLC cases
- 8 of 15 evaluable patients with non-squamous NSCLC showed objective response including 1 complete response (ORR 53% vs historical control data of 19%)
- 8 patients were 2nd line to pembrolizumab monotherapy, with 6 responses
- 40 additional patients to be recruited (combination with carboplatin/pemetrexed)

DEVELOPMENT ADVANCING TOWARDS RANDOMIZED TRIAL EARLY 2023

cantargia

CIRIFOUR – Broadening into IO combinations

- First arm (15 pts): Combination with pembrolizumab in patients no longer responding to PD-(L)1 therapy (NSCLC, HNSCC, malignant melanoma and bladder cancer)
- Very good safety, only one treatment related grade 3 AE (febrile neutropenia); 5 pts on treatment (2 >31 weeks; 2 >49 weeks); data update (incl. efficacy) at ASCO 2022
- Second arm (up to 24 pat): Combination with 1st line pembrolizumab and carboplatin/pemetrexed in non-squamous NSCLC starting Q2 2022
- Primary endpoint safety, secondary endpoints include biomarkers and efficacy

TRIAL DESIGNED TO ADVANCE NADUNOLIMAB OUTSIDE CHEMOTHERAPY COMBINATIONS
IMPORTANT STEP FOR COMBINATION WITH IO AND CHEMOTHERAPY

Cantargia to ASCO and present three studies

SIGNIFICANT UPDATES OF OUR CLINICAL RESULTS
HIGH INTERNATIONAL ATTENTION LEVEL

Cantargia

Advancing PDAC development to phase 2/3

PanCAN's Precision Promise℠ adaptive clinical trial platform designed together with the FDA

Nadunolimab selected for inclusion

- 15 leading US clinical centers - additional sites planned
- Patients randomized to receive nadunolimab with gemcitabine and nab-paclitaxel, or chemotherapy alone
- Bayesian design, successful completion of a 100-patient adaptively randomized Stage 1 may be followed by a 75-patient fixed-randomized Stage 2
- Trial results for nadunolimab arm expected 2027 or earlier
- Additional meetings with regulatory authorities to take place; pre-IND planned for submission to the US FDA in Q2 2022
- Cantargia funds nadunolimab arm and responsible for drug supply

ADVANCING WITH PANCAN FURTHER VALIDATES NADUNOLIMAB IN PDAC

Cantargia – Save lives and create value through IL1RAP

Project	Disease	Type of treatment	Discovery phase	Preclinical phase	Clinical phase I	Clinical phase II	Clinical phase III	Next steps
CAN04 Nadunolimab	PDAC	1st line	Gemcitabine/nab-paclitaxel					Interim update at ASCO and PanCAN pre-IND submission Q2 '22
			FOLFIRINOX					Initial safety readout H2 '22
	NSCLC	1st line	Cisplatin/gemcitabine					Interim update at ASCO Q2 '22
		2nd/3rd line	Docetaxel					Initial safety readout H2 '22
	Non-squamous NSCLC	1st/2nd line	Carboplatin/pemetrexed					Initial safety readout H2 '22
		1st line	Pembro/carboplatin/pemetrexed					FPI Q2 '22
	TNBC	1st/2nd line	Carboplatin/gemcitabine					Initial safety readout H2 '22
	Biliary tract cancer	1st line	Cisplatin/gemcitabine					Initial safety readout H2 '22
	Colon cancer	3rd line	FOLFOX					Initial safety readout H2 '22
	Solid tumors	ICI combo	Pembro					Interim update at ASCO Q2 '22
CAN10	Myocarditis; Systemic sclerosis							Initiation of Ph I early 2023
CANxx	New opportunities within IL1RAP platform							

■ recruitment ongoing; ■ recruitment completed; ■ non-clinical project; PDAC (pancreatic cancer); NSCLC (non-small cell lung cancer); TNBC (triple negative breast cancer)

PRIORITIZE MOST PROMISING OPPORTUNITIES

cantargia

Untapped possibilities in autoimmune diseases

CAN10 – New asset within autoimmunity/inflammation

- IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36
- Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation)
- Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on scientific rationale, medical need, development opportunity and competition.
- Clinical trial starts early 2023



UNIQUE OPPORTUNITY FOR CAN10 IDENTIFIED IN LIFE-THREATENING DISEASES

cantargia

CAN10 – Unique properties in preclinical disease models







CLINICAL TRIAL STRATEGY UNDER DESIGN TO VALIDATE PRECLINICAL RESULTS

cantargia

2022 and forward

Current altitude



We are in a strong position to further increase share holder value

antargia

Several upcoming value inflection points

Newsflow over next 6-9 months

Nadunolimab (CAN04)

- ASCO: New results for PDAC, NSCLC and Keytruda combination (CANFOUR, CIRIFOUR)
- Phase 2/3 Precision Promise (PDAC)
- New preclinical and translational results
- New clinical trials (Interim results, safety)
  - CAPAFOUR PDAC FOLFIRINOX
  - CESTAFOUR Basket trial (NSCLC, CRC, BTC)
  - TRIFOUR TNBC
- Prioritize clinical development towards most promising opportunities

CAN10

- Preclinical progress
- Development milestones
- …and initiation of clinical trial early 2023

SIGNIFICANT DATA TO SECURE NEWSFLOW